<DOC>
	<DOC>NCT01091376</DOC>
	<brief_summary>Concomitant chemoradiotherapy is the standard treatment of locally advanced,non-resectable, non-small cell lung cancer (NSCLC). However,the optimal chemotherapy regimen is still controversial.The objective of this study was to evaluate the efficacy and toxicity of a concomitant treatment using Erlotinib and radiotherapy followed by Erlotinib consolidation treatment.</brief_summary>
	<brief_title>Erlotinib Combined With Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)</brief_title>
	<detailed_description>Patients with non-resectable Non-small Cell Lung Cancer will receive thoracic radiation therapy 60-70 Gy over 30-35 fractions and concurrent with Erlotinib 150mg/day. Followed by Erlotinib 150 mg/day consolidation treatment.</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologically proven nonsmall cell lung cancer (squamous cell carcinoma, adenocarcinoma, large cell carcinoma and etc) Tumor EGFR mutation Presence of measurable disease by RECIST stage IIIA or IIIB, nonresectable ECOG performance status 02 No prior chemotherapy, radiation therapy to chest, immunotherapy, or biologic therapy Patients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policy of the hospital. Carcinoid tumor, small cell carcinoma of lung Patients with any distant metastasis History of another malignancy except cured basal cell carcinoma of skin and cured carcinoma insitu of uterine cervix Any other morbidity or situation with contraindication for radiotherapy (e.g. active infection, myocardial infarction preceding 6 months, symptomatic heart disease including unstable angina, congestive heart failure or uncontrolled arrhythmias, immunosuppressive treatment) Pregnant or lactating women, women who has not taken test of pregnancy (within 7 days before the first administration) and pregnant women Women and men of childbearing potential who have no willing of employing adequate contraception Tumor EGFR wild</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>EGFR-TKI</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Radiotherapy</keyword>
</DOC>